Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/AAC.02017-20 http://scihub22266oqcxt.onion/10.1128/AAC.02017-20 32967849!7674042!32967849     free     free     free       Antimicrob+Agents+Chemother 2020 ; 64 (12): ? Nephropedia Template TP {{tp|p=32967849|t=2020. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19) |pdf=|usr=}}{{32967849}} gab.com Text Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19) JO: Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32967849 #FOAvip It is becoming increasingly clear that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like most human viral infections, will require multiple drugs in combination to treat COVID-19 illness. In this issue of the Journal, Doi and colleagues describe successful treatment of patients with early COVID-19 with favipiravir, an oral polymerase inhibitor, to rapidly and substantially clear SARS-CoV-2 from nasal secretions irrespective if it was started relatively early or later within the first week of infection. These data support the concept that favipiravir could be paired with at least one more off-target antiviral agent (doxycycline, azithromycin, or ivermectin) followed by corticosteroids and antithrombotics to prevent COVID-19 hospitalization and death in those over age 50 and/or those with one or more comorbidities. Clinical trials and advanced practice should immediately pivot to combination/sequential drug therapy for ambulatory COVID-19 illness. Twit Text FOAVip Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19) ????Antimicrob Agents Chemother http://www.kidney.de/pget.php?&tw=1&pmid=32967849 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32967849 #FOAvip English Wikipedia <ref>{{Cite pmid|32967849}}</ref> Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19) #MMPMID32967849 McCullough PA Antimicrob Agents Chemother 2020[Nov]; 64 (12): ? PMID32967849show ga It is becoming increasingly clear that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), like most human viral infections, will require multiple drugs in combination to treat COVID-19 illness. In this issue of the Journal, Doi and colleagues describe successful treatment of patients with early COVID-19 with favipiravir, an oral polymerase inhibitor, to rapidly and substantially clear SARS-CoV-2 from nasal secretions irrespective if it was started relatively early or later within the first week of infection. These data support the concept that favipiravir could be paired with at least one more off-target antiviral agent (doxycycline, azithromycin, or ivermectin) followed by corticosteroids and antithrombotics to prevent COVID-19 hospitalization and death in those over age 50 and/or those with one or more comorbidities. Clinical trials and advanced practice should immediately pivot to combination/sequential drug therapy for ambulatory COVID-19 illness. |*Antiviral Agents/therapeutic use[MESH] |*Coronavirus Infections/drug therapy[MESH] |*Pandemics[MESH] |*Pneumonia, Viral/drug therapy[MESH] |*Severe Acute Respiratory Syndrome/drug therapy[MESH] |Amides[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |Humans[MESH] |Prospective Studies[MESH] |Pyrazines[MESH]Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 (epmc).pdf DeepDyve Pubget Overpricing